FOXO
vs
S&P 500
FOXO
S&P 500
Over the past 12 months, FOXO has underperformed S&P 500, delivering a return of -100% compared to the S&P 500's +13% growth.
Stocks Performance
FOXO vs S&P 500
Performance Gap
FOXO vs S&P 500
Performance By Year
FOXO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Foxo Technologies Inc
Glance View
FOXO Technologies, Inc. develops genetic sequencing technology artificial intelligence and bioinformatics tools. The company is headquartered in Minneapolis, Minnesota and currently employs 24 full-time employees. The company went IPO on 2020-12-11. The firm is focused on commercializing longevity science through products and services that serve the life insurance industry. Its epigenetic technology applies artificial intelligence (AI) to deoxyribonucleic acid (DNA) methylation to identify molecular biomarkers of human health and aging. The firm operates through two segments: FOXO Labs and FOXO Life. FOXO Labs is commercializing epigenetic biomarker technology to be used for mortality underwriting and risk classification in the global life insurance industry. Its biomarker technology enables the adoption of new saliva-based health and wellness biomarker solutions for underwriting and risk assessment. FOXO Life is redefining the relationship between consumers and insurers by combining life insurance with healthy longevity. FOXO Life seeks to transform the value proposition of the life insurance carrier from a provider of mortality risk protection products.
